Dabur India Limited

Sector: FMCG (Ayurveda, Personal Care, Foods, Healthcare)  |  HQ: Ghaziabad, Uttar Pradesh  |  Founded: 1884  |  Employees: ~7,500

Listed as: NSE / BSE listed; Nifty 50 constituent  |  NSE / BSE  |  Ticker: DABUR.NS  |  Website →

Key people

• Mohit Burman (Chairman)
• Mohit Malhotra (CEO)

Company overview

Dabur India Limited is one of India's oldest FMCG companies and the world's largest Ayurvedic and natural products company. Founded in 1884 by Dr S K Burman in Kolkata, Dabur is now headquartered in Ghaziabad and operates 21 manufacturing facilities globally (13 in India). FY25 consolidated revenue was approximately ₹12,500 crore. Iconic brands include Dabur Chyawanprash, Dabur Honey, Dabur Hajmola, Dabur Red Toothpaste, Dabur Amla, Vatika, Real Juice, Hommade, and the recently acquired Badshah Masala portfolio.

Business model

Dabur operates four reporting segments. Consumer Care (Healthcare, Personal Care, Foods) is the largest. International Business covers Middle East, Africa, US, UK exports. Foods grew through Real Juice acquisition and Badshah Masala acquisition. Healthcare covers Ayurvedic OTC and prescription products.

Operating segments

Recent developments

May 2026

Dabur India delivered a solid close to FY2026 with net profit surging 16% to Rs 362 crore for the quarter and full year ended March 31, 2026, prompting analysts to revise forecasts upward [9][2][3]. The company navigates inflationary pressure by prioritising margins over advertising spend, though Q4 advertising expenditure remained elevated on a year-over-year basis [8]. Senior leadership transitions are underway: Herjit S. Bhalla has been appointed CEO of the India Business [6][10], while Rahul Sarawagi has taken on the head of investor relations and M&A following Isha Lamba's departure [4]. Internationally, Dabur continues to expand its global footprint with a subsidiary incorporating US entity Pravaah Consumer Group and a separate venture forming Trustline Brands in the US FMCG space with $10,000 capital [1][7].

Sources (9)

1. Dabur subsidiary incorporates US entity Pravaah Consumer Group - scanx.trade · scanx.trade · Tue, 19 May 2026
2. Earnings Update: Dabur India Limited (NSE:DABUR) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - simplywall.st · simplywall.st · Sun, 10 May 2026
3. Dabur India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 - marketscreener.com · marketscreener.com · Thu, 07 May 2026
4. Dabur names Rahul Sarawagi as head of investor relations, M&A after Isha Lamba exit - Storyboard18 · Storyboard18 · Tue, 28 Apr 2026
5. Herjit S. Bhalla Appointed as Chief Executive Officer – India Business at Dabur India Limited - hrtoday.in · hrtoday.in · Fri, 24 Apr 2026
6. Dabur India Forms US FMCG Unit Trustline Brands with $10,000 - Whalesbook · Whalesbook · Wed, 06 May 2026
7. Dabur prioritises margins over ad spends amid inflation pressure; Q4 spends up YoY - Exchange4Media · Exchange4Media · Fri, 08 May 2026
8. Dabur India Ltd net profit surges 16% at Rs 362 cr - Adgully.com · Adgully.com · Thu, 07 May 2026
9. Dabur India Appoints Herjit S Bhalla as CEO – India Business - MediaNews4U · MediaNews4U · Fri, 24 Apr 2026

Financial performance and recent trajectory

Dabur reported FY25 revenue of ₹12,500 crore with EBITDA margin of approximately 19 percent. The Badshah Masala acquisition (₹588 crore) added to the foods portfolio. International business contributes approximately 22 percent of revenue.

Stock performance and shareholder context

Dabur (NSE: DABUR, BSE: 500096) is Nifty 50 constituent. Burman family trust holds approximately 67 percent.

12-month price trajectory

Monthly closes over the last 12 months. Source: Yahoo Finance.

Competitive position

Dabur leads Indian Ayurvedic FMCG ahead of Patanjali, Himalaya, and Emami in the natural-products segment.

Key risks

Slowing rural FMCG demand; competitive intensity from Patanjali and HUL Ayush range; juices category competition from PepsiCo Tropicana and Coca-Cola Minute Maid.

Outlook

Strong outlook on the secular growth of Ayurvedic FMCG and the rural India FMCG penetration trajectory.

KAMRIT point of view

Building or competing with Dabur?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the fmcg (ayurveda sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Dabur and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 4 related project reports → Book a scoping call

Related KAMRIT project reports

These reports use Dabur India Limited in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.